JENBURPHPharmaceuticals
Jenburkt Pharmaceuticals Ltd — Profit & Loss Statement
₹955.45
+0.34%
Jenburkt Pharmaceuticals Ltd Profit & Loss Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Tax Effect Of Unusual Items | 0.00 | 0.00 | 0.05 Cr | 0.07 Cr | — |
| Tax Rate For Calcs | 0.27 | 0.26 | 0.27 | 0.23 | — |
| Normalized EBITDA | 47.11 Cr | 37.79 Cr | 35.24 Cr | 31.82 Cr | — |
| Net Income From Continuing Operation Net Minority Interest | 32.06 Cr | 25.98 Cr | 24.61 Cr | 22.30 Cr | — |
| Reconciled Depreciation | 2.73 Cr | 2.34 Cr | 2.26 Cr | 1.90 Cr | — |
| Reconciled Cost Of Revenue | 29.66 Cr | 30.41 Cr | 33.81 Cr | 32.06 Cr | — |
| EBITDA | 47.11 Cr | 37.79 Cr | 35.42 Cr | 32.12 Cr | — |
| EBIT | 44.39 Cr | 35.45 Cr | 33.16 Cr | 30.22 Cr | — |
| Net Interest Income | -0.45 Cr | -0.27 Cr | 3.65 Cr | 3.94 Cr | — |
| Interest Expense | 0.45 Cr | 0.27 Cr | 0.30 Cr | 0.35 Cr | — |
| Normalized Income | 32.06 Cr | 25.98 Cr | 24.47 Cr | 22.07 Cr | — |
| Net Income From Continuing And Discontinued Operation | 32.06 Cr | 25.98 Cr | 24.61 Cr | 22.30 Cr | — |
| Total Expenses | 114.03 Cr | 111.19 Cr | 108.03 Cr | 98.37 Cr | — |
| Diluted NI Availto Com Stockholders | 32.06 Cr | 25.98 Cr | 24.61 Cr | 22.30 Cr | — |
| Net Income Common Stockholders | 32.06 Cr | 25.98 Cr | 24.61 Cr | 22.30 Cr | — |
| Otherunder Preferred Stock Dividend | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Income | 32.06 Cr | 25.98 Cr | 24.61 Cr | 22.30 Cr | — |
| Net Income Including Noncontrolling Interests | 32.06 Cr | 25.98 Cr | 24.61 Cr | 22.30 Cr | — |
| Net Income Continuous Operations | 32.06 Cr | 25.98 Cr | 24.61 Cr | 22.30 Cr | — |
| Tax Provision | 11.87 Cr | 9.20 Cr | 8.26 Cr | 7.57 Cr | — |
| Pretax Income | 43.93 Cr | 35.18 Cr | 32.86 Cr | 29.87 Cr | — |
| Other Non Operating Income Expenses | 6.72 Cr | 4.67 Cr | 0.11 Cr | 4.95 Cr | — |
| Net Non Operating Interest Income Expense | -0.45 Cr | -0.27 Cr | 3.65 Cr | 3.94 Cr | — |
| Interest Expense Non Operating | 0.45 Cr | 0.27 Cr | 0.30 Cr | 0.35 Cr | — |
| Operating Income | 37.66 Cr | 30.78 Cr | 28.11 Cr | 25.36 Cr | — |
| Operating Expense | 84.37 Cr | 80.78 Cr | 74.22 Cr | 66.31 Cr | — |
| Other Operating Expenses | 36.11 Cr | 35.95 Cr | 15.65 Cr | 3.74 Cr | — |
| Depreciation And Amortization In Income Statement | 2.73 Cr | 2.34 Cr | 2.26 Cr | 1.90 Cr | — |
| Depreciation Income Statement | 2.73 Cr | 2.34 Cr | 2.26 Cr | 1.90 Cr | — |
| Gross Profit | 122.03 Cr | 111.56 Cr | 102.33 Cr | 91.67 Cr | — |
| Cost Of Revenue | 29.66 Cr | 30.41 Cr | 33.81 Cr | 32.06 Cr | — |
| Total Revenue | 151.69 Cr | 141.97 Cr | 136.14 Cr | 123.73 Cr | — |
| Operating Revenue | 151.69 Cr | 141.97 Cr | 136.14 Cr | 123.73 Cr | — |
| Total Unusual Items | — | 0.15 Cr | 0.18 Cr | 0.30 Cr | 0.01 Cr |
| Total Unusual Items Excluding Goodwill | — | 0.15 Cr | 0.18 Cr | 0.30 Cr | 0.01 Cr |
| Interest Income | — | 4.13 Cr | 4.02 Cr | 4.37 Cr | 4.05 Cr |
| Rent Expense Supplemental | — | 0.28 Cr | 0.17 Cr | 0.19 Cr | 0.17 Cr |
| Diluted Average Shares | — | 0.44 Cr | 0.46 Cr | 0.46 Cr | 0.46 Cr |
| Basic Average Shares | — | 0.44 Cr | 0.46 Cr | 0.46 Cr | 0.46 Cr |
| Diluted EPS | — | 58.86 | 53.90 | 48.58 | 35.96 |
| Basic EPS | — | 58.86 | 53.90 | 48.58 | 35.96 |
| Special Income Charges | — | 0.01 Cr | 0.18 Cr | 0.30 Cr | 65000.00 |
| Other Special Charges | — | -0.01 Cr | -0.10 Cr | -0.22 Cr | -65000.00 |
| Write Off | — | 0.00 | -0.08 Cr | -0.08 Cr | 0.00 |
| Total Other Finance Cost | — | 0.04 Cr | 0.07 Cr | 0.09 Cr | 0.05 Cr |
| Interest Income Non Operating | — | 4.13 Cr | 4.02 Cr | 4.37 Cr | 4.05 Cr |
| Research And Development | — | 1.23 Cr | 1.23 Cr | 1.08 Cr | 0.98 Cr |
| Selling General And Administration | — | 16.50 Cr | 16.72 Cr | 23.17 Cr | 21.87 Cr |
| Selling And Marketing Expense | — | 11.85 Cr | 12.64 Cr | 20.00 Cr | 17.08 Cr |
| General And Administrative Expense | — | 4.65 Cr | 4.08 Cr | 3.17 Cr | 4.78 Cr |
| Rent And Landing Fees | — | 0.28 Cr | 0.17 Cr | 0.19 Cr | 0.17 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Jenburkt Pharmaceuticals Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.